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Abstract
It is of importance whether myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS)
is a variant of sickness behavior. The latter is induced
by acute infections/injury being principally mediated
through proinflammatory cytokines. Sickness is a
beneficial behavioral response that serves to enhance
recovery, conserves energy and plays a role in the
resolution of inflammation. There are behavioral/
symptomatic similarities (for example, fatigue, malaise,
hyperalgesia) and dissimilarities (gastrointestinal
symptoms, anorexia and weight loss) between
sickness and ME/CFS. While sickness is an adaptive
response induced by proinflammatory cytokines, ME/
CFS is a chronic, disabling disorder, where the
pathophysiology is related to activation of
immunoinflammatory and oxidative pathways and
autoimmune responses. While sickness behavior is a
state of energy conservation, which plays a role in
combating pathogens, ME/CFS is a chronic disease
underpinned by a state of energy depletion. While
sickness is an acute response to infection/injury, the
trigger factors in ME/CFS are less well defined and
encompass acute and chronic infections, as well as
inflammatory or autoimmune diseases. It is concluded
that sickness behavior and ME/CFS are two different
conditions.
Keywords: CFS, chronic fatigue, depression, inflam-
mation, ME, oxidative stress, sickness behavior
Introduction
Humans and animals use a range of autonomic, meta-
bolic and behavioral responses to combat acute infections
or injuries. Sickness behavior is a physiological behavioral
response principally induced and regulated by proinflam-
matory cytokines, including interleukin 1b (IL-1b), IL-6
and tumor necrosis factor (TNF)a, which act centrally to
induce sickness behaviors, including pyrexia. Proinflam-
matory cytokines modify the activity of hypothalamic
neurons causing an increase of the thermoregulatory set
point [1]. In addition, animals and humans display symp-
toms such as fatigue, malaise, hyperalgesia, neurocogni-
tive disorders, sleepiness, anhedonia, anorexia and weight
loss, as well as diminished food intake, social activities,
locomotor activity, grooming and exploration [2,3]. Sick-
ness behaviors are viewed as adaptive responses, which
facilitate recovery from acute infections or injuries [2,3].
Sickness behaviors, including fever, are postulated to
offer a survival benefit in endothermic and ectothermic
vertebrates [4]. The sickness response is conserved by
evolution and has an adaptive function in enabling survi-
val of individuals and species in the face of assault by a
myriad of microbial pathogens and injuries [5]. Stereoty-
pical patterns of sickness are displayed by mammals,
birds, reptiles and even invertebrates [6]. In summary,
(a) this proinflammatory cytokine-induced sickness
response is short lasting, evolutionarily conserved, and
beneficial to the organism; and (b) many of the sickness
behaviors are valuable in conserving energy and therefore
to combat and attenuate the inflammatory response
caused by infections or inflammatory trauma [3,7].
Myalgic encephalomyelitis/chronic fatigue syndrome
(ME/CFS) is a disabling disorder that can have a greater
impact on functional status and well-being than many
other chronic, life-threatening diseases [8,9]. ME/CFS
is associated with a dramatic decrement in physical
* Correspondence: dr.michaelmaes@hotmail.com
4Barwon Health, School of Medicine, Deakin University, PO Box 291, Geelong,
3220, Australia
Full list of author information is available at the end of the article
Morris et al. BMC Medicine 2013, 11:64
http://www.biomedcentral.com/1741-7015/11/64
© 2013 Morris et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
functioning [10] with patients scoring significantly lower
on most of the eight Medical Outcome Study (MOS)
36-item Short-Form (SF-36) health survey subscales
when compared with patients with cardiovascular and
neurological disorders, as well as higher on depression
measures [8]. Typical symptoms of ME/CFS are: physi-
cal and mental fatigue, pain, muscle weakness, neuro-
cognitive impairment, sleep disturbances, depression,
gastrointestinal symptoms, a subjective feeling of infec-
tion or a flu-like malaise and post-exertion fatigue or
malaise [11,12].
Thus, there are important behavioral/symptomatic
similarities between both ME/CFS and sickness behavior.
Moreover, activated immunoinflammatory pathways play
a role in the pathophysiology of ME/CFS, for example,
increased proinflammatory cytokine levels [13]. As such,
both sickness behavior and ME/CFS share common phe-
nomenological and biochemical aspects. These findings
led some authors to conclude that ME/CFS and sickness
behaviors are a manifestation of a common pathophysiol-
ogy with other neurophysiological mechanisms of sick-
ness behavior being similarly extrapolated to ME/CFS
and related conditions [14]. Other authors maintain that
ME/CFS is fundamentally a more chronic version of
acute sickness behavior [15]. The latter authors in fact
change the meaning of the term sickness behavior and
use the term to describe a situation where the sickness
behavioral complex and the inflammatory condition per-
sist. This situation should then be recognized as persis-
tent sickness behavior or ME/CFS.
A further confounding factor is the diagnosis and sub-
typing of ME/CFS. There are different diagnostic criteria
used to make the diagnosis of ME/CFS, generating consid-
erable controversy. According to a commonly used diag-
nostic classification for ME/CFS, Fukuda’s criteria [16],
ME/CFS is accompanied by chronic fatigue lasting for
more than 6 months and at least four additional symptoms
(sore throat, tender lymph nodes, neurocognitive disor-
ders, multiple joint pain, muscle pain, headache, non-
refreshing sleep or post-exertion malaise (PEM) lasting
more than 24 h). The diagnosis of ME/CFS according to
Fukuda’s criteria, however, defines a heterogeneous group
of patients [11]. Recently, we have provided evidence sug-
gesting that ME/CFS patients should be divided into those
with and without post-exertion malaise into ME and CFS,
respectively. Doing so, it was defined that ME and CFS are
qualitatively distinct diagnostic classes [11].
Another major confound is the common perspective
within psychosocial psychiatry to consider ME/CFS as a
condition triggered by excessive rest in predisposed indivi-
duals following acute triggers [17]. This perspective places
ME/CFS within a psychosocial and psychiatric framework.
Recently, we have incorporated aspects of this within a
biological model with psychosocial aspects contributing to,
and themselves being driven by, inflammatory and related
pathways, providing a more parsimonious explanation
based on biological underpinnings [17].
In the present work, we review: (a) the phenomenologi-
cal similarities and dissimilarities between sickness beha-
vior and ME/CFS, (b) the course of sickness behavior
versus ME/CFS, (c) the immunoinflammatory-related
pathways that underpin or may discriminate both sickness
and ME/CFS, and (d) the differences in etiologic factors
that trigger both conditions.
Phenomenological similarities between sickness
behavior and ME/CFS
Symptoms typical of sickness behavior are described
above. The phenomenological experience of acute viral or
bacterial infection involves malaise, a lack of motivation or
lassitude, with accompanying fatigue bordering on exha-
ustion. Other responses include numbness, shivering,
impaired appetite and weight loss, as well as aches and
pains in muscles and joints [3].
Table 1 summarizes the similarities and dissimilarities
between sickness behavior and ME/CFS. People with
ME/CFS have a wide range of classically conceptualized
psychosomatic, but recently reframed physiosomatic,
symptoms [11-13]. Typical symptoms include fatigue and
chronic exhaustion. These symptoms include unrelenting
severe disabling mental and physical fatigue combined
with disabling levels of muscle fatiguability. Hyperalgesia,
muscle pain and tension, migraine type headaches,
insomnia, hypersomnia, non-refreshing sleep or sleep
wake cycle reversal are typical symptoms of ME/CFS.
Problems with memory retrieval can manifest as an
inability to finish sentences, negatively feeding back on
self-esteem and subjective wellbeing. These symptoms
are exacerbated by cognitive and or physical activity.
Intolerance to even trivial increases in physical or mental
activity above individual norms is the hallmark symptom
of ME [10-12,17,18]. This intolerance manifests itself as
marked worsening of symptoms that may be short lived
or prolonged (sometimes weeks) but only rarely resulting
in permanent disability [10,11]. Post-exertion malaise
indicates the intense malaise, exhaustion or neurocogni-
tive symptoms following physical or mental activities and
lasting for more than 24 h. This typical symptom in ME
corresponds with the fatigue and exhaustion behaviors
expressed during sickness behavior.
Malaise, a key aspect of sickness behavior, is also a
major feature of ME/CFS. Many individuals with ME/CFS
display symptoms normally associated with severe influ-
enza, for example, including a flu-like malaise or the sub-
jective feeling of infection [11]. This symptom scores
highly on two symptomatic dimensions of ME/CFS
pathology; that is, a sickness dimension that loads highly
on neurocognitive disorders, depression, and autonomic
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Table 1 Characteristics of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior
Category ME/CFS Sickness behavior
Physiosomatic
symptoms
Disabling fatigue Fatigue, lethargy, behavioral inhibition
Mental fatigue Reduction of exploration
’Pacing’ as an energy-conservation strategy Reduced locomotor activity
Post-exertion malaise following mental/physical activities Fatigability
A flu-like malaise Malaise, flu-like symptoms
Hyperalgesia Hyperalgesia
Muscle tension and pain Muscle pain
Sleep disorders Sleepiness
High incidence of autonomic symptoms Probably yes, but not well documented
Failure to concentrate Failure to concentrate




May occur when comorbid depression is present Disinterest in social interactions




May occur when comorbid depression is present Anorexia and weight loss
Pyrexia Slightly increased body temperature in a few patients Pyrexia
Onset Acute onset or insidious Acute onset
Course Waxing and waning or progressive course Acute adaptive response
Chronic course (>6 months) Maximal 19 to 43 days
Energy
metabolism
Mitochondrial dysfunction, lowered ATP, abnormally high
lactate levels
Is an adaptive behavioral response aiming to conserve energy and
to redirect energy to immune cells to combat the pathogens
Is an adaptive response to counteract negative energy balance
Impaired oxidative phosphorylation Sickness behavior plays a key role in the resolution of acute
inflammation
When the energy stores are depleted and the acute inflammation is
not resolved, chronic inflammation ensues
Structural mitochondrial abnormalities
Accelerated glycolysis; decreased phosphocreatine synthesis
rates following exercise
Pathways (Sub)chronic inflammation with increased proinflammatory
cytokines
Acute inflammation with increased proinflammatory cytokines
Cell-mediated immune (CMI) activation Probably activated
Simultaneous T helper (Th)1 and Th2 responses -
Multiple immune dysfunctions -
Lowered antioxidant levels -
Reactive oxygen species (ROS)/reactive nitrogen species (RNS) Probably yes
Damage by oxidative and nitrosative stress (O&NS) to lipids,
DNA, proteins
-
Autoimmune responses to O&NS modified neoepitopes -
Autoimmunity -
Reduced hypothalamic-pituitary-adrenal (HPA) axis function in
some patients
Enhanced HPA axis activity (part of compensatory (anti)-
inflammatory reflex system (CIRS))
Triggers Multiple, not well defined Acute, highly defined
Long-term effects of acute infection Acute pathogens and tissue injury
Disease exacerbated by infections -
Disease exacerbated by psychological stress -
Chronic medical inflammatory illness -
Chronic neuroinflammatory disorders -
Autoimmune disorders -
Sometimes no trigger factor is observed Is always a response to a defined trigger
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disorders and a hyperalgesia dimension that loads highly
on muscle pain and tension and headache. This could be
seen as analogous to the malaise theory of depression,
which considers malaise as a key feature of depression [7],
which we have recently shown could not be validated, as
only some depressed patients experience malaise [19].
However, this highlights the phenomenological and bio-
chemical overlaps among depression, somatization and
ME/CFS [20].
Depressive-like behaviors, including reduction of loco-
motor activity, anhedonia (reduced intake of sweetened
milk in rodent models), anorexia and weight loss are
characteristics of sickness behavior and are not specific
to ME/CFS. However, there are high rates of comorbidity
between ME/CFS and depression. Subclinical and full-
blown clinical depression frequently accompany ME/CFS
[21]. Moreover, measures of clinical depression and ME/
CFS show high comorbidity, with clinical depression
being the most prevalent comorbidity with ME/CFS in
some studies [22]. This has led some to propose that
ME/CFS is a form of clinical depression [23]. In addition,
depressive symptoms, such as sadness, are included in
rating scales, such as the Fibromyalgia and Chronic Fati-
gue Syndrome Rating Scale [24]. Thus, in fact, patients
with ME/CFS may have anorexia, weight loss, and so on,
when they also have clinical depression. However, clus-
ters of physiosomatic symptoms coupled to increases in
immunoinflammatory pathways are significant common-
alities in depression and ME/CFS, suggesting significant
phenomenological and biochemical similarities that may
be relevant to overlaps in subtyping and treatment [20].
Nevertheless, clinical depression and ME/CFS are differ-
ent syndromes, which may be discriminated with a high
predictive value using severity of post-exertion malaise,
percentage of time fatigue reported, shortness of breath,
unrefreshing sleep, confusion/disorientation and self-
reproach [25].
Other differences between sickness behavior and ME/
CFS are pyrexia and gastrointestinal symptoms. Pyrexia is
one of the key symptoms of sickness behavior and plays a
role in the defense against acute infections and acute
injury. Mild and moderate fever prevents viral replication
and enhances crucial functions of polymorphonuclear leu-
kocytes, including mobility and killing of bacteria [3]. The
effects of proinflammatory and cell-mediated immune
(CMI) cytokines, including interferons, are more active
during fever [3]. There is, however, no evidence of pyrexia
in ME/CFS. Nevertheless, the onset of ME/CFS as defined
by fatigue, arthralgias, myalgias and a chilly sensation may
be accompanied by low-grade pyrexia [26]. In a small pro-
portion of fatigued individuals, fatigue and isolated fever
may apparently persist without organic pathology [27]. In
contrast to sickness behavior, many patients with ME/CFS
have gastrointestinal symptoms as measured by the Fibro-
myalgia and Chronic Fatigue Syndrome Rating Scale [24].
Gastrointestinal symptoms, reminiscent of irritable bowel
syndrome (IBS), are considered to be diagnostic criteria in
new ME and ME/CFS case definitions [10,11]. In addition,
these gastrointestinal symptoms may have a specific
inflammatory pathophysiology, including via increased
bacterial translocation [12].
ME/CFS patients display signs of autonomic nervous
system dysfunction [28,29] and although not typically
described as core symptoms of sickness behavior these
symptoms may also occur during acute inflammatory
conditions. Neurally mediated hypotension and ortho-
static intolerance are the most commonly documented
cardiovascular symptoms in ME/CFS. The latter abnorm-
ality in particular correlates with the severity of disease
[30,31]. Postural orthostatic tachycardia syndrome is
another common finding. Exaggerated postural tachycar-
dia and enhanced sympathetic activity have been
reported [28]. Intolerance of wide temperature changes
and markedly impaired thermostatic stability are other
commonly reported manifestations of autonomic dys-
function. A subdued cardiac response to exercise has
been reported [32] and sympathetic hyperactivity coupled
with reduced vagal modulation are reproducible findings
[33]. De Becker et al. [34] detected a sympathetic drive
mediated increased heart rate on tilt compared to healthy
controls. Another study demonstrated impaired heart
rate responses to exercise coupled with globally impaired
hemodynamic responses incompatible with patient
deconditioning or prolonged inactivity [35]. Several other
Table 1 Characteristics of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior
(Continued)
Risk factors IgG, IgG1 and IgG3 deficiencies -
Immune gene polymorphisms -
Reduced ω3/ω6 ratio -
General Inflammation, O&NS and mitochondrial-related chronic
progressive disorder
Inflammation-induced adaptive behavioral and CIRS response that is
conserved through evolution
Janus face Bad ‘chronic’ side: a chronic disorder with positive feedback
loops between inflammatory responses and autoimmune
processes
Beneficial ‘acute’ side: supports inflammation, redirects energy to
immune cells, conserves energy and prevents negative energy
balance, helps eradicating the trigger, and has anti-inflammatory
effects
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authors have reported autonomic dysfunctions in people
with ME/CFS [36-38].
In summary, cross-sectionally there is a phenomenologi-
cal overlap between sickness behavior and ME/CFS, both
presenting with malaise, hyperalgesia, fatigue, exhaustion,
sleepiness, failure to concentrate, and sometimes mood
disturbances. PEM following mental and physical activ-
ities, a characteristic symptom of ME, may also occur dur-
ing sickness behavior. Other symptoms or behaviors,
however, discriminate ME/CFS and sickness behavior. For
example, gastrointestinal symptoms reminiscent of IBS
[10,11] occur in many ME/CFS patients but not typically
in sickness behavior. Anorexia and weight loss, typical
symptoms of sickness, are not germane to ME/CFS unless
there is comorbid depression. While pyrexia is a hallmark
of the acute inflammation during sickness, mild fever may
occur in a small proportion of ME/CFS patients. Phenom-
enologically, the acute sickness response demonstrates
some overlap with ME/CFS but the range of symptoms
experienced by people with ME/CFS is much wider than
in sickness behavior.
Course: sickness behavior versus ME/CFS
Sickness behavior is conceptualized as a short-term
response to acute infections or injuries. Sickness is an
adaptive behavioral response that is appropriate to coun-
teract acute bacterial or viral infections or inflammatory
trauma and therefore plays a role in the resolution of
inflammation and thus recovery. ME/CFS, on the contrary,
is an enduring disorder with a relapsing-remitting or
chronic course [12,39]. Using international consensus cri-
teria for ME/CFS, most studies report a waxing and wan-
ing or progressive pattern of this disease [40-42]. In
contrast to sickness behavior, which is a short-lasting, ben-
eficial behavioral response, the recovery rate from ME/
CFS is very low [40-42]. For example, in studies using
CDC criteria the recovery rate was only 4% [40,42]. In
another prospective study carried out over 12 months,
none of the patients recovered, while 40% of the indivi-
duals with ME/CFS did not improve, 20% showed a pro-
gressive course, and 40% showed a relative improvement
in their symptoms [43].
Recent use of the terms prolonged, persistent or inap-
propriately sickness behavior has emerged. Within this ter-
minological perspective, ME/CFS and sickness behavior
may be regarded as manifestations of a shared pathophy-
siology, with ME/CFS viewed as an expression of persis-
tent increases in proinflammatory cytokines following an
episode of acute inflammation. We have argued that
attaching the terms prolonged, exaggerated or persistent
to sickness behavior is unsatisfactory, primarily due to
sickness behavior by definition, being a short-lasting, bene-
ficial behavioral response that plays a role in the resolution
of inflammation [3]. As discussed above, some authors
consider that the sickness responses may persist when the
production of proinflammatory cytokines, for example fol-
lowing gut and hepatic inflammation or choleostasis, is no
longer restricted to the periphery, but also becomes estab-
lished systematically, and perhaps prolonged, within the
CNS [44-46]. Prolonged fatigue and depression, however,
are not generally viewed as adaptive behaviors but are
more parsimoniously seen as dysfunctional [7] as is the
case in autoimmune disorders or persistent infections.
Therefore, these conditions cannot be termed sickness
behavior (defined as an acute adaptive response), with
these patients more likely to have secondary depression,
CFS or ME perhaps as a result of pre-existing genetic or
epigenetic priming that alters the longer-term conse-
quences of infection and other stressors.
’Persistence’ of inflammation is in our opinion not an
adequate term and should better be labeled as ‘transition
from an acute inflammatory response to a chronic inflam-
matory state’. The ‘transition’ label stresses that the path-
ways underpinning the pathophysiology of chronic
inflammation and chronic inflammatory disease are dis-
tinct from the beneficial mechanisms that determine sick-
ness behavior [3]. In this respect it was shown that such
transition towards chronic inflammatory conditions may
play a role not only in ME/CFS but across a range of dif-
ferent diseases, for example, post-trauma illness, malaria,
sepsis, and so on [15]. There is a further overlap between
sickness behavior as a physiological construct, and abnor-
mal illness behavior as a psychological/behavioral con-
struct. The latter overlaps with illness investment and the
sick role, and may be concurrent or overlapping phenom-
ena [47].
In summary, while sickness behavior is a short-lasting,
adaptive and acute inflammatory state, ME/CFS is a
chronic disorder characterized by a waxing and waning or
progressive pattern with an extremely low recovery rate
(see Table 1).
Neuroimmune pathways in sickness behavior and
ME/CFS
Energy metabolism in sickness behavior versus ME/CFS
Acute inflammatory conditions consume large amounts of
energy, whereby adipose and muscle tissues and glycogen
are used to provide energy to combat pathogens [48]. This
causes a negative energy balance; that is, the expended
usage of calories is greater than the intake. Lowered synth-
esis of muscle proteins, proteolysis, and lipolysis and loss
of tissue proteins and fats are typically induced by proin-
flammatory cytokines produced in response to invading
pathogens in injured tissues [48]. The objective of the sick-
ness response from an evolutionary perspective is energy
conservation [3,7,15]. Proinflammatory cytokines, such as
TNFa, not only modulate a negative energy balance to
compensate for the increased energy demands but also
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reduce food intake by causing anorexia and decreased
voluntary energy utilization [48]. Characteristic sickness
behavior symptoms, such as lethargy, sleepiness, fatigue,
listlessness, malaise, hyperalgesia, psychomotor retarda-
tion, loss of libido and cognitive deficits aim to limit highly
energy-consuming processes, such as motor, sexual and
brain activities [3]. As such, energy that otherwise would
be consumed for locomotor, reproductive and neurocogni-
tive activities is withdrawn from the brain, muscles and
other peripheral tissues and redirected to fuel the calorie-
dependent activities of immune cells [2,3,7,15]. Thus, the
typical sickness behaviors save energy and contribute to
redirecting the conserved energy to immune cells as well
as to pyrogenic and other inflammatory processes. As
such, sickness behaviors, in shifting resources to a pat-
terned immune response, help to combat acute infection
or injury.
Moreover, by inducing anorexia (and thus restricting
calorie intake), intracellular signaling pathways associated
with inflammation are attenuated. This includes those
leading to IL-6 production [49]. Calorie restriction addi-
tionally attenuates lipopolysaccharide (LPS)-induced sick-
ness behavior in a dose-dependent manner [50].
Therefore, we have argued that sickness behavior is part of
the compensatory (anti)-inflammatory reflex system
(CIRS), which is induced in response to inflammatory pro-
cesses [3]. Thus, sickness behavior augments the beneficial
effects of inflammation and at the same time limits an
overzealous inflammatory response [3,50]. The increased
energy expenditure and anorexia leading to the negative
energy balance eventually causes loss of body fat, protein
mass and thus lean body mass and therefore may lead to
inflammation-associated weight loss [3]. Weight loss
results in anti-inflammatory effects attenuating the pro-
duction of, for example, IL-6 and TNFa and increasing
that of endogenous anti-inflammatory compounds, for
example, adiponectin [3]. Thus, not only proinflammatory
cytokine-induced anorexia but also the consequent weight
loss is a homeostatic adaptive response, which should be
considered as part of the CIRS [3].
Finally, energy saving sickness behaviors, such as fatigue,
listlessness, loss of libido, and neurocognitive disorders,
not only play a role in the resolution of inflammation but
are crucial in preventing the transition from acute to
chronic inflammation. Thus, by saving energy and com-
pensating for the negative energy balance sickness beha-
viors prevent inflammatory sequelae, such as depletion of
energy stores, cachexia, anemia, osteopenia and insulin
resistance, which determine the transition towards chronic
inflammation [51]. The transition from acute to chronic
inflammation occurs around 19 to 43 days after the onset
of the acute phase of inflammation [51]. Chronic inflam-
mation ensues when the acute inflammatory response and
the CIRS, including sickness behavior, were not able to
eradicate the primary infectious agent or heal the injury,
for example, pyogenic bacteria, viral infections, fungi, sar-
coidosis, and autoimmune responses [52].
ME/CFS, however, is a chronic disease, which is accom-
panied by an inability to generate energy on demand [12].
Mitochondrial dysfunctions and abnormally low ATP and
high lactate levels play a role in ME/CFS [12,53-61]. ME/
CFS patients display exercise-induced exhaustion much
earlier than healthy controls. When reaching exhaustion,
ME/CFS patients display diminished intracellular ATP
and dysregulated oxidative metabolism, coupled to
increased glycolysis in the exercising striated muscles
[12,58]. ME/CFS patients display reduced rates of ATP
resynthesis in the aftermath of exercise versus controls
resulting from impaired oxidative phosphorylation [56].
Patients with ME/CFS show prolonged elevations of lac-
tate, returning extremely slowly to normal levels [53,59].
Behan et al. [55] found histopathological abnormalities in
the mitochondria of skeletal muscles in ME/CFS. During
exercise, the latter display decreased voluntary muscle
contractions, which worsen subsequently [59]. Thus, in
ME/CFS patients reduced intracellular ATP, oxidative
metabolism and accelerated glycolysis in skeletal muscles
determine early exhaustion [12,58,61]. Several studies
report significantly increased levels of ventricular lactate in
ME/CFS patients, suggesting central energy dysregulation
[62,63].
We previously proposed that the defects in energy
production and mitochondrial functions in ME/CFS are
probably caused by chronic inflammatory and oxidative
and nitrosative stress (O&NS) processes [12,58]. Thus,
raised levels of proinflammatory cytokines resulting
from systemic inflammation disable oxidative phosphor-
ylation within mitochondria. This is reflected in the
increased lactate and mitochondrial dysfunction com-
monly seen in chronic inflammatory states [64]. For
example, TNFa causes a marked decrease in mitochon-
drial membrane potential, which may increase reactive
oxygen species (ROS) [65] and increases mitochondrial
membrane permeability leading to membrane depolari-
zation [66]. Increased ROS damages the electron trans-
port chain leading to depleted ATP production, which
in turn causes a deficiency in oxidative phosphorylation
leading to overt mitochondrial disease [67]. Defects in
oxidative phosphorylation leads to increased ROS pro-
duction, which acts to create self-propagating mitochon-
drial dysfunction [68] contributing to increased IL-1b
and IL-18 via inflammasome induction [69]. Mitochon-
drial shutdown induced by proinflammatory cytokines is
ultimately engineered by nitric oxide (NO) and is rever-
sible [70]. NO signaling regulates mitochondrial number
and function [71] and inhibits mitochondrial respiration
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[72] by competing with oxygen at complex 1 and
cytochrome oxidase [73] resulting in diminished ATP
production. Peroxynitrite inhibits mitochondrial respira-
tion by modulating electron transport complexes I and
III [74]. Attenuation of mitochondrial respiration by for
example NO or its derivatives activates ROS and reactive
nitrogen species (RNS) produced by mitochondria [75].
In addition, the increased levels of nuclear factor (NF)B
observed in ME/CFS [76] contribute to a shift towards
aerobic glycolysis (the Warburg effect) as observed in
cancer cells [58].
Kennedy et al. [54] reported elevated surrogate bio-
markers of O&NS in ME/CFS, which positively asso-
ciated with symptom exacerbation following energy
expenditure. Fatigue results from ROS accumulation
and diminished availability of ATP in muscle cells [77].
As to how this relates to the putative subtypes of Booth
et al. [78], where ME/CFS patients are subdivided on
the basis of decreased ADP uptake by mitochondria ver-
sus decreased ATP output requires further investigation.
These two subgroups are predicted to differentially
show increased lactate production and altered ability for
repeat exercise. It is not unlikely that changes in oxida-
tive status, lipid peroxidation and mitochondrial mem-
brane rigidity are impacting on the activity of the ADP-
ATP translocator (TL), perhaps having differential
effects on TL uptake or output functions. Around 20%
of mitochondria in cells at any given point in time are
in the process of transport, either exhausted and being
removed from sites of high-energy need or fresh mito-
chondria are being imported into such sites. Further
investigation is required as to whether the energetic
changes in mitochondria in ME/CFS contribute to dys-
regulated signaling for transport. This may overlap with
the genetic susceptibility to ME/CFS mediated by
changes in the disrupted-in-schizophrenia 1 (DISC1)
gene, which is associated with mitochondrial transport
[79]. ATP is also an important neuronal and glia trans-
mitter. As to how altered mitochondrial ATP regulation
modulates such wider ATP functions is unknown, but
would be expected to contribute to cognitive deficits,
especially in high energy demand activities of the ventral
lateral prefrontal cortex that are required to unhook
specific memory exemplars.
In summary, energy metabolism plays a key role in sick-
ness behavior and ME/CFS and also differentiates sickness
from ME/CFS. Table 1 and Figure 1 show the differences
in energy metabolism between both conditions. Thus,
sickness behaviors aim to conserve and redirect energy to
immune cells, preventing transition from acute to chronic
inflammation. ME/CFS, however, shows chronic dysfunc-
tions in ATP and lactate production, caused by peripheral
and central mitochondrial dysfunctions, driven, in part, by
chronic inflammation and O&NS.
Immunoinflammatory pathways in sickness versus ME/
CFS
Elevated levels of proinflammatory cytokines drive most
if not all aspects of the sickness response either directly
or indirectly [80]. Proinflammatory cytokines, including
IL-1, IL-6, and TNFa, activate the production and/or
release of secondary inflammatory mediators, such as
prostaglandins (PGs) and NO [81]. Proinflammatory
cytokines directly stimulate numerous neurohormonal
systems. A variety of mechanisms allow proinflammatory
cytokine signals to circumnavigate of the blood brain bar-
rier [82]. Blood borne proinflammatory cytokines can dif-
fuse through relatively permeable areas of the blood
brain barrier via the circumventricular organs [6], allow-
ing proinflammatory cytokines to directly interact with
microglia and astrocytes in the glia limitans. Another
crucial pathway involves a complex series of interactions
between proinflammatory cytokines and brain endothe-
lial cells [3]. The third pathway involves the activation of
neurons by proinflammatory cytokines via the vagus
nerve and catecholaminergic circuits of the sympathetic
nervous system (SNS) [12]. (For a more detailed exami-
nation of immune to brain communication, see [83].)
Interestingly, the production of TNFa persists in the
brain much longer than in the periphery [84-86], while
TNFa additionally passes both ways across the blood-
brain barrier [87]. This is concordant with chronic neu-
roinflammation and low-grade peripheral inflammation
being interconnected phenomena. Within the brain,
proinflammatory cytokines, prostaglandins and NO
invoke brain responses to infection in the periphery [88].
Once microglia are activated, astrocytes are recruited
leading to further activation of neuroinflammatory sig-
nals [89]. Thus, both cell types collaborate to propagate
neuroinflammation and the physiological changes direc-
ted at diminishing the replication of pathogens increasing
the metabolism of carbohydrate fat and protein [90] and
generating energy-conserving behaviors [3].
The central nervous system (CNS) modulates the
immune response via two pathways: (a) the hypothala-
mic-pituitary-adrenal (HPA) axis and (b) the release of
catecholamines and acetylcholine [91]. Communication
of proinflammatory cytokine signaling to the brain via
the vagus provokes a rapid anti-inflammatory response
through increased HPA axis and cholinergic nerve activ-
ity [92]. This forms the basis of the CIRS response
including the HPA axis, cholinergic and anti-inflamma-
tory responses [3]. This CIRS response in the CNS and
autonomous nervous system generates its own character-
istic symptom pattern (for example, autonomic symp-
toms) and is thus part of the sickness response. The SNS
modulates the immune response at systemic, local and
regional levels [93]. Catecholamines inhibit production of
proinflammatory and T helper (Th)1 cytokines, while
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enhancing the synthesis of Th2 cytokines together with
IL-10 and transforming growth factor (TGF) 1 [94]. Acet-
ylcholine release through activation of the parasympa-
thetic nervous system attenuates the production of IL-1,
TNFa and IL-6 [91].
Such mechanisms underpinning the sickness response
reveals it as an automated irresistibly integrated response
conserved by evolution and which is induced by proin-
flammatory cytokines, including IL-1 and TNFa. The
relation between elevated proinflammatory cytokines and
fatigue and fatiguability is well documented [95]. Elevated
proinflammatory cytokines are largely responsible for the
severe fatigue seen in multiple sclerosis [96], cancer-
related fatigue and cognitive symptoms [97], fatigued
breast cancer survivors [98], and the debilitating fatigue
reported by underperforming athletes [99]. Inhibition of
IL-1b is associated with a 50% reduction in fatigue in
patients with Sjögren’s syndrome [100]. Proinflammatory
cytokines and prostaglandin E2 (PGE2) mediate inflam-
matory hyperalgesia [95] as well as neurocognitive
abnormalities leading to problems with concentration
and memory [95,101]. Many of these adverse effects
especially in the CNS are mediated by IL-1b [102]. The
hippocampus is the hub of processes involving learning
and memory and is also the region of the brain with the
highest levels of IL-1 receptors and is especially vulner-
able to the effects of neuroinflammation [103]. While
physiological levels of IL-1 are essential in the develop-
ment of memory and learning, elevated endogenous


























Figure 1 Summary of differences between sickness behavior and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Sickness behavior is a short-lasting, adaptive and acute inflammatory state induced by acute infection/trauma, while ME/CFS is a disabling
chronic disorder associated with multiple, less well defined triggers. While sickness behavior is an acute inflammatory response to
proinflammatory cytokines (PICs), ME/CFS is accompanied by a chronic low-grade inflammatory state and a mixed T helper (Th)1 and Th2
response, immune dysfunctions, autoimmune responses and activation of oxidative and nitrosative stress (O&NS) pathways. PIC-induced sickness
behavior aims to conserve energy, redirect energy to fuel immunocytes and prevent transition from acute to chronic inflammation. ME/CFS,
however, is accompanied by chronic mitochondrial dysfunctions in energy metabolism, for example, reduced ATP production, which are driven,
at least in part, by chronic inflammatory and O&NS processes. When there is no resolution of acute inflammation, a chronic inflammatory and
thus pathological state may ensue that may lead to the development of ME/CFS some months later.
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abnormal behaviors [104,105]. IL-1b also mediates the
suppression of feeding behavior and appears to regulate
lipid metabolism by antagonizing the performance of
lipoprotein lipase, which is the principal regulator of lipid
store mobilization in the body [106]. IL-1b and NFB are
essential mediators of the anhedonic effects of sickness
behaviors [107]. Moreover, IL-1b in concert with TNFa
inhibits sexual behavior [108]. TNFa and IL-1b suppress
the clock genes that regulate circadian rhythm and hence
could influence a veritable myriad of biological functions.
The net effect of the action of these cytokines on clock
genes is to reduce the metabolic rate and the demand for
energy in the form of ATP [15].
In patients with ME/CFS, proinflammatory cytokines,
including IL-1b and TNFa, are elevated and are signifi-
cantly associated with the severity of fatigue, a flu-like
malaise, sadness and autonomic symptoms [95]. This
together with the findings that these proinflammatory
cytokines may cause similar sickness behaviors suggest
that increased levels of proinflammatory cytokines may
contribute to selected ME/CFS symptoms [95]. However,
in ME/CFS activation of immunoinflammatory pathways
and intracellular signaling networks, including NFB,
inducible nitric oxide synthase (iNOS) and cyclooxygen-
ase 2 (COX-2) and CMI pathways contribute to fatigue,
malaise, hyperalgesia, and autonomic and neurocognitive
symptoms [12,13,95]. Moreover, there are many more
immunoinflammatory related differences between sick-
ness behavior and ME/CFS, including the following.
(1) Elevated levels of proinflammatory cytokines may be
associated with a number of other biological disorders that
are observed in ME/CFS. For example, as explained in the
previous section, TNFa affects energy metabolisms and
leads to defects in mitochondria. TNFa also reduces the
number of mitochondrial cristae and inhibits mitochon-
drial respiration. TNFa causes opening of mitochondrial
permeability transition pores (PTP) leading to a disappear-
ance of the inner membrane potential and the uncoupling
of oxidative phosphorylation [12]. Proinflammatory cyto-
kines also induce O&NS pathways and by generating an
increase in ROS in the electron transport chain deplete
glutathione [109]. Proinflammatory cytokine elevations in
general lead to the upregulation of NADPH oxidase [110],
generating superoxide anions and reactive oxygen depen-
dent damage, ultimately leading to the formation of perox-
initrite and membrane damage by lipid peroxidation
[111,112]. IL-6 also dramatically increases the rate of glu-
cose usage in striated muscle [113].
(2) Numerous immunoinflammatory abnormalities are
also seen in people with ME/CFS indicating an activated
but dysregulated immune system, including high levels of
serum neopterin [13,95], which is a surrogate marker for
increased interferon (IFN)g levels [114]. High neopterin
concentrations occur in diseases with activated Th1 type
immune responses, including viral infections, a number
of autoimmune diseases and several neurodegenerative
diseases [115]. Elevated IFNg levels deplete tryptophan in
the plasma and the brain via activation of indoleamine-
2,3-dioxygenase as can be observed in chronic active viral
infection [116].
(3) It is worth emphasizing at this point that much of
the symptoms and pathology driven by proinflammatory
cytokines occurs transiently in sickness behavior, but
occurs chronically in ME/CFS. Far from being a Th2
dominated illness it is now clear that Th1 and Th2 cyto-
kines coexist in ME/CFS [12,58]. Moreover, the cytokine
profile in ME/CFS patients changes markedly over time
[117]. Chronic elevation of Th2 and Th1 cytokines may
conspire to create additional and more complex patholo-
gies, for example, accelerating the rate of glucose homeos-
tasis in the brain [118]. Other well documented immune
abnormalities in ME/CFS, which are not germane to sick-
ness behavior, include dysregulated forkhead box P3
(FoxP3) expression [119], disrupted T cell homeostasis as
indicated by reports of increased CD26 expression [120],
decreased expression of CD69 [121] and elevated B cell
numbers [122].
(4) A plethora of other immune abnormalities have been
detected in patients with ME/CFS, which when taken
together demonstrate the existence of a dysregulated
immune system. These findings include reduced natural
killer cell function and T cell exhaustion [12,58,119-122].
T cell exhaustion and the Th2 response may suggest that
ME/CFS is accompanied by activation of the CIRS, as can
be observed in many other inflammatory disorders [3,12].
In summary, there is some evidence that shared inflam-
matory pathways (that is, increased proinflammatory cyto-
kine levels) underpin sickness behavior and determine
part of the symptoms in ME/CFS (see also Table 1). How-
ever, while sickness behavior is a beneficial response
induced by proinflammatory cytokines to conserve energy
and combat pathogens thus preventing transition to
chronic inflammation, ME/CFS is a chronic inflammatory
disorder accompanied by a combined Th1 and Th2
response and multiple signs of a seriously dysregulated
immune system.
O&NS pathways in sickness versus ME/CFS
Other pathways that discriminate sickness behavior from
chronic inflammatory disorders are reduced antioxidant
levels and increased O&NS, driving O&NS damage to
lipids, DNA, proteins and mitochondria (see above).
Inflammatory processes, CMI activation and O&NS pro-
cesses are inseparably associated. For example, phagocytes
and activated M1 macrophages produce large amounts of
ROS and RNS [123]. CMI activation produces neopterin,
increasing ROS and RNS [124]. O&NS processes also acti-
vate the production of proinflammatory cytokines and
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T cells [125]. Therefore sickness behavior may be accom-
panied by elevated levels of ROS/RNS, which help to era-
dicate invading pathogens, that then normalize with the
resolution of inflammation.
ME/CFS, however, shows chronically increased ROS/
RNS, O&NS processes and O&NS damage, including
increased malondialdehyde (MDA), isoprostane, 2,3
diphosphoglyceric acid, 8-OH-deoxyguanosine, protein
carbonyls and thiobutyric acid [126-130]. iNOS produc-
tion is significantly higher in ME/CFS patients versus
controls [131]. As discussed in the next section, ME/CFS
is accompanied by a chronic hyperproduction of NO
[95,126]. Raised oxidative stress levels also occur in
response to exercise in ME/CFS [129] potentially explain-
ing one of the mechanisms underlying post-exertion
malaise [12]. Skeletal muscle oxidative imbalance contri-
butes to increased muscle fatiguability [130].
Lowered levels of coenzyme Q10, zinc and glutathione
have been reported in ME/CFS [126,127,131] with ameli-
oration of oxidative stress occurring during remission
[128]. As well as decreased coenzyme Q10 [127], decreased
vitamin C and E will impact mitochondrial function,
increasing lipid peroxidation. Such effects are potentially
prevented by melatonin [132], as shown after strenuous
exercise in humans [133]. Maes et al. [134] reported signif-
icantly increased ω6 lineolic and arachidonic acids in
ME/CFS, driving a reduced ω3 to ω6 polyunsaturated fatty
acids (PUFAs) ratio versus controls, contributing to
inflammation in ME/CFS [135].
Such alterations can generate pathology via a number
of mechanisms. Isoprostane, a prostaglandin (PG)F2-like
compound, correlates positively and significantly with
general ME/CFS disease severity as well as the magnitude
of exercise induced disease exacerbation [54]. Elevated
MDA promotes phospholipids rigidity, altering mem-
brane fluidity, permeability and transport mechanisms
[136]. Importantly, elevated MDA decreases mitochon-
drial membrane fluidity [137]. A decrease in melatonin,
found in some ME/CFS studies, would contribute to
increased mitochondrial membrane rigidity [138], as well
as reduced natural killer cell activity in ME/CFS [119].
Melatonin also modulates aspects of sickness behaviors
[139], inhibiting NFB induction and microglia activation
[140], suggesting that variations in melatonin may con-
found the comparison of processes in ME/CFS and sick-
ness behavior.
In summary, while sickness behavior is probably accom-
panied by increased ROS/RNS, which should normalize
upon the resolution of inflammation, ME/CFS is accompa-
nied by chronically activated O&NS processes causing
chronic damage to lipids, DNA, proteins and mitochon-
dria. While in sickness behavior the putative increase in
ROS/RNS would be an adaptive response, increased
O&NS largely underpins the pathophysiology of ME/CFS.
Autoimmune responses in ME/CFS
Autoimmune processes also frequently occur in ME/CFS
and are not germane to a beneficial short-term response
as sickness behavior. IgM autoimmune responses directed
against oxidatively damaged lipid membrane components
(for example, oleic acid), anchorage molecules (for exam-
ple, palmitic and myristic acid and S-farnesyl-L-cysteine),
residue molecules of lipid peroxidation (for example, aze-
laic acid and MDA), and amino acids or proteins modified
by nitrosylating species (for example, NO-tyrosine,
NO-phenylalanine, NO-tryptophan, NO-arginine, and
NO-cysteine) have all been reported [12,126]. These reac-
tions are directed against neoantigenic determinants
(neoepitopes), which are created as a result of damage to
lipids and proteins by O&NS [12,126,141]. These antigenic
structures are normally invisible to the immune system
but become targeted because structural modifications
induced by elevated O&NS have rendered them immuno-
genic. The levels of these corrupted entities correlate posi-
tively and significantly with the severity of selected
ME/CFS symptoms, such as fatigue, muscle pain, a flu-like
malaise, and so on [12,126].
Reports of frank autoimmune reactions are common-
place in people with ME/CFS. Antibodies to cardiolipin,
nuclear envelope antigens and neuronal antigens have all
been reported [12,142-145]. Several teams have reported
elevated titers of autoantibodies directed towards ganglio-
sides, serotonin, phospholipids, anti-68/48K and microtu-
bule associated proteome as well as anti-lamin single
stranded DNA [145-147]. Autoantibodies against muscari-
nic cholinergic receptors, mu-opioid receptors and dopa-
mine receptors have been detected [148]. Autoantibodies
directed against ganglioside M1, for example, play a role
in neuroimmune disorders, correlating with neurocogni-
tive dysfunctions as observed in neuropsychiatric systemic
lupus erythematosus [149,150].
HPA axis function in sickness and ME/CFS
Sickness behaviors induced by different challenges and in
different species are accompanied by marginally increased
to significantly increased plasma corticosterone levels
[151]. Moreover, corticosterone causes sensitization of
LPS-induced pyrexia and pain, but not lethargy, and leads
to enhanced sickness-induced neuroinflammation [152].
IL-1, via upregulation of prostaglandin and COX enzymes,
enhances HPA axis activation [153] and hypothalamic
norepinephrine synthesis [154]. IL-1b also increases brain
tryptophan concentrations and the rate of 5- hydroxytryp-
tamine (5-HT) metabolism, which may further activate the
HPA axis [154]. Given glucocorticoid anti-inflammatory
effects, HPA axis activation is part of the CIRS response
[3]. Glucocorticoids also significantly regulate immune
genes and cell functions, for example, decreasing the
Th1/Th2 ratio [155]. Moreover, glucocorticoids participate
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in programmed cell death and energy-related processes,
for example, glucose, lipid, protein and carbohydrate
homeostasis [155,156].
The activation of the HPA axis in sickness behavior
contrasts the findings in ME/CFS. HPA axis hypoactivity
is a characteristic feature in some people with ME/CFS
[157,158], for example, low baseline levels of HPA axis
hormones, aberrant diurnal hormone levels, reduced
HPA axis responses to provocation by corticotropin-
releasing hormone (CRH) or adrenocorticotropic hor-
mone (ACTH), blunted HPA axis responses to physical
and psychological stress, and enhanced sensitivity to
glucocorticoids [159-165]. This lowered HPA activity
may be explained by prolonged stimulation of O&NS
and immunoinflammatory pathways in ME/CFS. For
example, chronic elevations of IL-6 may blunt the
release of ACTH [166]. TNFa may inhibit the stimula-
tion of CRH, ACTH-induced cortisol release and adre-
nal gland function [167,168].
In summary, while sickness behavior is accompanied
by HPA axis activation as part of a CIRS, ME/CFS is
accompanied by lowered HPA axis activity, which may
be secondary to activation of immunoinflammatory and
O&NS pathways (see Table 1).
Leptin: sickness versus ME/CFS
Leptin is an important mediator of infection-induced
inflammation and sickness behaviors [169,170]. However,
leptin also accelerates the recovery from hypoxia-induced
sickness behavior via an increase in IL-1 receptor antago-
nist (IL-1RA) [171]. Obese rodents show an altered
inflammatory and behavioral response to infection [172].
Treatment of ME/CFS with low dose hydrocortisone
increases leptin, leading to a favorable treatment response
[173]. Interestingly, recent data shows leptin as a risk fac-
tor for, and displaying efficacy in the treatment of depres-
sion, as well as Alzheimer’s disease [174-176]. Leptin, like
melatonin, is a wide immune regulator, increasing natural
killer cell activity and Th1 responses, while inhibiting the
cAMP induction of tryptophan 2,3-dioxygenase (TDO) in
astrocytes, thereby inhibiting cognitive deficits mediated
by TDO induction of kynurenic acid. The severity of
ME/CFS is associated with increased indicants of meta-
bolic syndrome [177], suggesting that wider metabolic dys-
regulation associated with obesity and leptin resistance will
modulate the course and perhaps etiology of ME/CFS.
Thus, leptin may have significant and differential regula-
tory effects in ME/CFS and sickness behaviors.
Trigger factors in sickness behavior and ME/CFS
Sickness behavior is an adaptive CIRS response induced
by acute injuries or bacterial and viral infections. These
phenomenological experiences combined with pyrexia
and neuroendocrine changes represent an integrated
hierarchal system conserved by evolution to combat infec-
tion, conserve energy, play a role in the resolution of
inflammation and limit an overzealous inflammatory
response [3]. When resolution of inflammation is not
induced or when the inflammatory response is overzea-
lous, a chronic inflammatory state may emerge [52,178].
The consequent chronic inflammatory state is then loca-
lized where the trigger, either infection or injury, was pre-
sent leading to persistent infections and medical disorders
related to the affected organs or systemic immunoinflam-
matory and O&NS responses [3,179].
In contrast to the role of acute infection/injury in sick-
ness behavior, different trigger factors such as acute and
chronic infections, environmental factors and other medi-
cal disorders may play a role in ME/CFS. Depending on
the applied case definitions, the presence of medical ill-
nesses may sometimes be regarded as exclusion criteria
for a diagnosis of CFS [16]. Thus, Fukuda’s criteria con-
sider that the fatigue should not be caused by any condi-
tions that may be identified by specific tests or diagnoses
[16]. Other criteria however make the presence of neu-
roendocrine symptoms and intolerance of mental or phy-
sical exercise mandatory [10]. The latter authors propose
that a strategy be developed which could detect patients
with a neuroimmune condition rather than focus on
patient populations that have fatigue whose origin is not
revealed by routine medical testing or explained by any
psychiatric condition. Moreover, we have argued that
ME/CFS may be caused by other inflammatory disorders,
including multiple sclerosis, autoimmune disorders, and
so on, and that in these conditions also the diagnosis
ME/CFS or ME/CFS due to general medical condition
should be made [12,17].
Upper respiratory system and flu-like infections often
precede the onset of ME/CFS [180]. ME/CFS often occurs
in epidemics suggesting that infections may cause
ME/CFS [181]. Bacterial and viral infections, including
Epstein-Barr virus (EBV), Coxiella burnetii, Parvo B19 and
Mycoplasma, are well known trigger factors associated
with the onset of ME/CFS [182]. However, infections not
only trigger ME/CFS but may also function as maintaining
factors. Thus, many patients with ME/CFS have persistent,
recurrent or opportunistic bacterial and viral infections
[183,184]. These infections may maintain ME/CFS or
cause relapses [185]. Moreover, the number and severity
of symptoms, including neurological symptoms, is corre-
lated with the existence of concurrent infections [186,187].
Gene expression data show latent viral or bacterial infec-
tions in ME/CFS, for example, Epstein-Barr virus, entero-
viruses and C. burnetii [188-190]. Other infections that are
associated with this disorder are, among others, human
herpesvirus (HHV) 6 and 7, cytomegalovirus, entero-
viruses, Borna disease virus, Chlamydia pneumoniae and
Borrelia burgdorferi [182].
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In summary, sickness behavior and ME/CFS are related
to infections. One major difference, however, is that sick-
ness behavior is a short-lasting, adaptive response to
acute infection, whereas recurrent or opportunistic infec-
tions play a role in the severity and in the relapsing and
chronic course of ME/CFS. While sickness behavior is
caused by acute infections, the onset of ME/CFS may
sometimes be associated with the long-term effects of an
acute infection, such as long-standing neuroinflamma-
tion, O&NS processes or the onset of autoimmune reac-
tions. Moreover, it is probable that when an initial
infection is not cleared and/or there was no resolution of
inflammation, a chronic infection with activation of
immunoinflammatory and O&NS processes may ensue.
Arguably these processes may be associated with the
onset of ME/CFS. By inference, in some patients who
initially showed sickness behaviors in response to an
acute infection, ME/CFS may develop. From a clinical
point of view, the transition from acute (sickness beha-
vior) to chronic inflammation occurs between 19 to 43
days. According to the diagnostic criteria of ME and CFS
[10,16], the patient cannot be diagnosed as having ME/
CFS until 6 months after the onset of the disease. This
means that patients, even when experiencing chronic
inflammatory processes and from ME/CFS symptoms,
cannot be diagnosed as ME/CFS between days 19 to 43
and 6 months. Prolonged or persistent sickness behaviors
for this period are not adequate labels because sickness
behavior denotes an adaptive and acute inflammatory
response, whereas the patients after 19 to 43 days are
already in a chronic inflammatory state. Therefore, we
propose that those patients should be categorized as hav-
ing chronic fatigue (CF), a diagnosis which then should
be changed into CFS or ME some months later [11].
In contrast to sickness behavior, the initial trigger in
ME/CFS is not always well defined, while the chronic
stage is associated with positive feedback loops between
inflammatory processes and degenerative and autoim-
mune processes [95,189]. Thus, CFS and ME show a simi-
lar pattern to other chronic degenerative disorders in
which the initiating trigger is not well defined, for exam-
ple, clinical depression, schizophrenia, multiple sclerosis,
Parkinson’s disease, inflammatory bowel disease, cancers,
including breast cancer, and autoimmune disorders, lupus
erythematosus, Sjögren’s syndrome and rheumatoid arthri-
tis, and so on. Moreover, patients with these disorders
are primed to develop CF and CFS (and probably ME)
through activated immunoinflammatory and O&NS path-
ways [12,95]. For example, the prevalence of CF/CFS is
very high in the above-mentioned autoimmune (41% to
81%) and inflammatory disorders, such as ankylosing
spondylitis, biliary cirrhosis, post-poliomyelitis and psoria-
tic arthritis (48% to 50%) [191]. In post-stroke patients,
fatigue is associated with inflammatory biomarkers [192].
Pascoe et al. [193] reviewed that post-stroke depression is
caused by inflammatory and O&NS processes. By infer-
ence, similar processes may explain the onset of post-
stroke fatigue. Research also showed a significant associa-
tion between fatigue and cardiovascular disease (CVD),
another inflammatory and O&NS disease [194]. There is
also an increased incidence of chronic fatigue in hemodia-
lysis patients (’hemodialysis fatigue’) [195]. Since hemodia-
lysis is accompanied by inflammatory and O&NS
processes, the latter could also explain the increased inci-
dence of fatigue during hemodialysis. In the postpartum
period, another inflammatory state, increased levels of fati-
gue were found with a significant overlap between postna-
tal fatigue and depressive symptoms [196]. IFNa-based
immunotherapy not only causes clinical depression
through induction of the cytokine network, but also by an
increased incidence of fatigue and CFS-like symptoms
[197,198]. Increased bacterial translocation is also asso-
ciated with the onset of ME/CFS [199]. Loosening of the
gut barrier may allow poorly invasive Gram-negative bac-
teria to translocate from the gut into the mesenteric
lymph nodes and sometimes into the blood stream. Once
translocated, the LPS is recognized by the Toll-like recep-
tor 4 (TLR4) complex, which primes immune cells and
consequently activates inflammatory and O&NS pathways
[12,199].
Psychological stressors are also associated with the
onset of ME/CFS [200]. Psychosocial stress also increases
the frequency of relapses or a general worsening of symp-
toms [17]. This may be explained by psychological stress
leading to elevated levels of proinflammatory cytokines
and O&NS processes that may well create the environ-
ment that fosters increased disease activity [201].
In contrast to sickness behavior, which is a CIRS
response to infection/injury, a number of pathological
predisposing factors may increase the vulnerability to
develop ME/CFS. For example, IgG subclass deficien-
cies, vitamin D deficits, immune gene polymorphisms
and a lowered ω3/ω6 PUFA ratio are observed in ME/
CFS [12,134]. IgG1 and IgG3 subclass deficiencies
increase the risk to infections and autoimmune and
inflammatory responses and thus to ME/CFS [12,185].
A decrease in vitamin D is associated with ME/CFS,
decreasing not only bone density, but also increasing
the susceptibility to, and severity of, infections [202], in
part via the regulation of NFB [203]. Genetic poly-
morphisms in TNFa, IFNg, IL-17, IL-10 and HLA genes
are associated with the onset of ME/CFS [145]. The
DISC1 gene is a susceptibility factor for ME/CFS, as
well as for schizophrenia and depression [204]. DISC1
has a significant role in early development, including in
the regulation of neuronal migration [205]. Given the
relevance of altered mitochondrial function to ME/CFS,
it is interesting that DISC1 is strongly associated with
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mitochondria, significantly regulating mitochondrial
function and transport [79]. A possible role of early life
immune insult has been proposed for ME/CFS, suggest-
ing that the immune system may be primed by prenatal
and postnatal immune regulatory events for an altered
response to infection [206]. The lowered ω3/ω6 ratio
detected in ME/CFS patients predisposes towards
inflammatory and autoimmune responses as ω3 PUFAs
are strongly anti-inflammatory and ω6 PUFAs proin-
flammatory [134].
Conclusions
Both sickness behavior and ME/CFS show a phenomeno-
logical overlap, both presenting with fatigue, malaise,
hyperalgesia, sleepiness, neurocognitive symptoms and
mood symptoms. Post-exertional malaise following mental
and physical activities, a characteristic symptom of ME,
probably also occurs during sickness behavior. While gas-
trointestinal symptoms are diagnostic criteria for some
case definitions of ME/CFS, these symptoms are not typi-
cal for sickness behavior. Some typical sickness behavior
Multiple, less well defined triggers
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Figure 2 Comparison of the characteristics of sickness behavior and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). While
there are significant phenomenological overlaps between sickness behavior and ME/CFS there are major symptomatic differences, such as
gastrointestinal symptoms, anorexia, weight loss, psychomotor retardation and pyrexia. Increased levels of proinflammatory cytokines (PICs) may
induce the above-mentioned behaviors/symptoms and therefore explain the partial symptomatic overlap between sickness behavior and ME/CFS.
While sickness is a short-lasting, beneficial response to acute inflammation, ME/CFS is a disabling disorder with a waxing and waning or progressive
pattern and a very low recovery rate. While sickness is a response to acute triggers, the onset of ME/CFS is associated with multiple less well defined
trigger factors. While sickness is induced by increased PICs, ME/CFS is accompanied by chronic low-grade inflammation and associated (auto)immune
disorders and oxidative and nitrosative stress (O&NS). While sickness is accompanied by activation of the hypothalamic-pituitary-adrenal (HPA) axis,
some patients with ME/CFS display HPA axis hypofunction. While acute sickness behaviors aim to conserve energy and prevent transition of acute to
chronic inflammation, chronic inflammatory and O&NS pathways conspire to create a state of chronic energy depletion in ME/CFS. In contrast to
sickness, predisposing factors increase the vulnerability to develop ME/CFS, including interferon (IFN)g, interleukin and DISC1 (disrupted in
schizophrenia-1) gene polymorphisms. CA = breast carcinoma; CVD = cardiovascular disease; IBD = inflammatory bowel disease; MS = multiple
sclerosis; PD = Parkinson’s disease; PsA = psoriatic arthritis; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus.
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symptoms, such as psychomotor retardation, anorexia and
weight loss do not occur in ME/CFS unless there is comor-
bid depression. While pyrexia is a hallmark of acute inflam-
mation, mild fever may occur in a few patients with
ME/CFS. While sickness behavior is a short-lasting, adap-
tive and acute inflammatory state, ME/CFS is a chronic
disorder characterized by a progressive or relapse-remitting
course and with an extremely low recovery rate. While
proinflammatory cytokines induce the beneficial sickness
behavior response, ME/CFS is accompanied by chronic
low-grade inflammation, O&NS, autoimmune responses,
and wider immune alterations. Proinflammatory cytokines
and Th1 cytokines and other inflammatory mediators
together with elevated O&NS can induce a wide range of
empirical abnormalities and disabling symptoms. These
molecules conspire to create other differences between the
acute sickness response, which is a state of proinflamma-
tory cytokine-induced energy conservation, and ME/CFS,
which is a chronic disease underpinned by a state of
chronic energy depletion [12]. In contrast to sickness beha-
vior, which is a CIRS response to acute infection/injury,
the initial trigger in ME/CFS is not always well defined and
encompasses acute and chronic infections, multiple auto-
immune and (neuro)inflammatory diseases and psychoso-
cial stressors. In contrast to sickness behavior, some
specific risk factors predispose to develop ME/CFS, for
example, IgG deficiencies, immune gene polymorphisms
and reduced ω3/ω6 PUFA ratio. While sickness behaviors
are halted with the resolution of inflammation, ME/CFS is
a chronic disorder associated with positive feedback loops
between inflammatory and O&NS processes as well as
degenerative and autoimmune processes. Table 1 and
Figure 2 shows that sickness behavior and ME/CFS are
two different conditions; that is, an adaptive beneficial
response to proinflammatory cytokines on the one hand,
and a chronic inflammation/O&NS-related disabling disor-
der on the other.
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tryptophan 2,3-dioxygenase; TGF: transforming growth factor; Th: T helper;
TNF: tumor necrosis factor.
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